

CROMOC

About RDP Pharma AG

RDP Pharma (RDP) is a privately held biotech dedicated to the vision that their products will deliver valuable medicines to patients in need.

RDP's leadership team and board of directors are focused on getting their products into clinical trials and addressing the unmet medical needs of patients. The team comprises entrepreneurs, drug development experts, and biotech veterans. Their extensive experience ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented.

About Next Generation Drug Delivery Module: DDM

The use of the DDM is a novel and more versatile, simpler, and more efficient approach to targeted conveyance with the following benefits:

- Efficient drug delivery – an order of magnitude higher than current cell-penetrating peptides
- Delivery of high molecular mass cargo
- Optimized drug-like properties
- Straightforward production
- Improved tissue selectivity
- Broad range of targets accessible

The delivery of large biomolecules into cells has been a challenge for decades. Initial approaches using cell penetrating peptides lacked efficiency and exhibited disadvantageous production and pharmacokinetic properties. We have developed a proprietary DDM which facilitates the efficient cellular uptake of cargo, enabling the transport of small drugs as well as biomolecules with high molecular masses. The delivery module can readily be attached to future drug candidates for systemic application due to optimization regarding pharmacokinetics, bio-distribution, toxicology, and production. Enrichment in specific compartments can be realized using different proprietary DDM sequences. Applications using a wide range of endonucleases have been successfully tested and indicate the potential to develop a broad range of novel DDM-based therapeutics.

About CROMOC – First in Class of the DDM Family

CROMOC contains a sorting DDM. CROMOC biomolecules preferentially target tumor cells through cleavage of active chromatin. CROMOC has been profiled in several forms of cancer, including liver and lung cancer.

Partnering with RDP

We are seeking partners/investors to support the expansion of our technologies and the clinical development of CROMOC.

Interested parties should contact Dr. Michael Ahrweiler:

michael.ahrweiler@rdp-pharma.com